Granules India’s arm gets EIR with NAI status for packaging facility in US

05 Mar 2026 Evaluate

Granules India’s US step-down subsidiary -- Granules Consumer Health, LLC has received an Establishment Inspection Report (EIR) with a No Action Indicated (NAI) Status from the US Food and Drug Administration (FDA) for its packaging facility in Manassas, Virginia, U.S.

The FDA inspection was conducted at the company’s packaging facility in Manassas, Virginia, from December 1 to 3, 2025. This marks the facility’s second FDA inspection, following the March 2023 audit, which also concluded with zero observations.

Granules Consumer Health serves as Granules’ front-end division for OTC products in the U.S., leveraging Granules India’s manufacturing efficiencies, regulatory compliance, and integrated supply chain. This facility is responsible for packaging both OTC and prescription (Rx) products and serving as a distribution hub for OTC products across the US.

Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).

Granules India Share Price

573.80 20.30 (3.67%)
05-Mar-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1782.90
Dr. Reddys Lab 1313.05
Cipla 1326.00
Zydus Lifesciences 914.45
Lupin 2332.40
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×